Brief: Sensei Biotherapeutics Announces Clinical Data From Ongoing Phase 1/2 Combination Trial Of SNS-301 In Patients With Squamous Cell Carcinoma Of The Head And Neck

Faeth Therapeutics,

19/05/2021 22:15

May 19 (Reuters) - Sensei Biotherapeutics Inc  SNSE.O :
    * SENSEI BIOTHERAPEUTICS ANNOUNCES NEW CLINICAL DATA FROM
THE
ONGOING PHASE 1/2 COMBINATION TRIAL OF SNS-301 IN PATIENTS WITH
SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    * SENSEI BIOTHERAPEUTICS INC - DATA CONTINUE TO SHOW THAT
SNS-301
IN COMBINATION WITH PEMBROLIZUMAB IS WELL TOLERATED
    * SENSEI - ONE DEEP AND DURABLE PARTIAL RESPONSE AND TWO
LONGSTANDING STABLE DISEASES OBSERVED IN PATIENTS WITH NO
RESPONSE TO PRIOR PD-1 BLOCKADE
    * SENSEI - SAFETY PROFILE OF SNS-301 IN COMBINATION WITH
PEMBROLIZUMAB OBSERVED FROM 20 EVALUABLE PATIENTS WAS
FAVORABLE,CONSISTENT WITH PREVIOUS DATA

Source text for Eikon:  ID:nGNX6PGfJY 
Further company coverage:  SNSE.O 

 ((Reuters.Briefs@thomsonreuters.com;))